Cargando…

Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study

PURPOSE: To report the preliminary results of oscillatory photodynamic therapy (OPDT) for choroidal neovascularization (CNV) and central serous retinopathy (CSR). METHODS: This study included 7 eyes of 6 patients with CSR (2 eyes), idiopathic CNV (2 eyes), CNV due to age-related macular degeneration...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyman, Gholam A, Tsipursky, Michael, Nassiri, Nariman, Conway, Mandi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ophthalmic Research Center 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306098/
https://www.ncbi.nlm.nih.gov/pubmed/22454731
_version_ 1782227181541261312
author Peyman, Gholam A
Tsipursky, Michael
Nassiri, Nariman
Conway, Mandi
author_facet Peyman, Gholam A
Tsipursky, Michael
Nassiri, Nariman
Conway, Mandi
author_sort Peyman, Gholam A
collection PubMed
description PURPOSE: To report the preliminary results of oscillatory photodynamic therapy (OPDT) for choroidal neovascularization (CNV) and central serous retinopathy (CSR). METHODS: This study included 7 eyes of 6 patients with CSR (2 eyes), idiopathic CNV (2 eyes), CNV due to age-related macular degeneration (AMD) (2 eyes), and peripapillary CNV secondary to presumed ocular histoplasmosis syndrome (1 eye). Intravenous verteporfin (6 mg/m(2) body surface area) was infused over 10 minutes followed by oscillating laser (wavelength 689 nm) covering slightly beyond the entire lesion. An Area Centralis lens was applied and laser was delivered (600 mW/cm(2) fluence rate and 50 J/cm(2) dose). Intravitreal bevacizumab and dexamethasone combination therapy was used with OPDT in 4 eyes with CNV; intravitreal dexamethasone and triamcinolone acetonide were injected in the other eye with CNV. Clinical examination, funduscopy, fluorescein angiography, and optical coherence tomography (OCT) were performed at baseline and after treatment. RESULTS: After mean follow-up of 7.1±5.1 months, visual acuity improved from 0.87±0.69 logMAR (20/160) to 0.60±0.65 logMAR (20/80) (P = 0.027); central foveal thickness decreased from 322±62.1 to 240.7±34.8 microns as measured by OCT (P = 0.018). Fluorescein angiography and OCT demonstrated cessation of vascular leakage, and resolution of hemorrhage and subretinal fluid in all eyes. No adverse events or recurrence were noted. CONCLUSION: OPDT was effective in treating CNV lesions and CSR. OPDT may be an improvement on standard PDT due to reduced side effects, thermal damage and scarring.
format Online
Article
Text
id pubmed-3306098
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ophthalmic Research Center
record_format MEDLINE/PubMed
spelling pubmed-33060982012-03-27 Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study Peyman, Gholam A Tsipursky, Michael Nassiri, Nariman Conway, Mandi J Ophthalmic Vis Res Original Article PURPOSE: To report the preliminary results of oscillatory photodynamic therapy (OPDT) for choroidal neovascularization (CNV) and central serous retinopathy (CSR). METHODS: This study included 7 eyes of 6 patients with CSR (2 eyes), idiopathic CNV (2 eyes), CNV due to age-related macular degeneration (AMD) (2 eyes), and peripapillary CNV secondary to presumed ocular histoplasmosis syndrome (1 eye). Intravenous verteporfin (6 mg/m(2) body surface area) was infused over 10 minutes followed by oscillating laser (wavelength 689 nm) covering slightly beyond the entire lesion. An Area Centralis lens was applied and laser was delivered (600 mW/cm(2) fluence rate and 50 J/cm(2) dose). Intravitreal bevacizumab and dexamethasone combination therapy was used with OPDT in 4 eyes with CNV; intravitreal dexamethasone and triamcinolone acetonide were injected in the other eye with CNV. Clinical examination, funduscopy, fluorescein angiography, and optical coherence tomography (OCT) were performed at baseline and after treatment. RESULTS: After mean follow-up of 7.1±5.1 months, visual acuity improved from 0.87±0.69 logMAR (20/160) to 0.60±0.65 logMAR (20/80) (P = 0.027); central foveal thickness decreased from 322±62.1 to 240.7±34.8 microns as measured by OCT (P = 0.018). Fluorescein angiography and OCT demonstrated cessation of vascular leakage, and resolution of hemorrhage and subretinal fluid in all eyes. No adverse events or recurrence were noted. CONCLUSION: OPDT was effective in treating CNV lesions and CSR. OPDT may be an improvement on standard PDT due to reduced side effects, thermal damage and scarring. Ophthalmic Research Center 2011-07 /pmc/articles/PMC3306098/ /pubmed/22454731 Text en http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Peyman, Gholam A
Tsipursky, Michael
Nassiri, Nariman
Conway, Mandi
Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study
title Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study
title_full Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study
title_fullStr Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study
title_full_unstemmed Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study
title_short Oscillatory Photodynamic Therapy for Choroidal Neovascularization and Central Serous Retinopathy; a Pilot Study
title_sort oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306098/
https://www.ncbi.nlm.nih.gov/pubmed/22454731
work_keys_str_mv AT peymangholama oscillatoryphotodynamictherapyforchoroidalneovascularizationandcentralserousretinopathyapilotstudy
AT tsipurskymichael oscillatoryphotodynamictherapyforchoroidalneovascularizationandcentralserousretinopathyapilotstudy
AT nassirinariman oscillatoryphotodynamictherapyforchoroidalneovascularizationandcentralserousretinopathyapilotstudy
AT conwaymandi oscillatoryphotodynamictherapyforchoroidalneovascularizationandcentralserousretinopathyapilotstudy